Company intelligence

StimCardio Medical

As of October 30, 2026, StimCardio Medical has raised at least $30M in equity across 1 sourced funding round.

Biotech

StimCardio Medical at a glance

As of
Equity raised
$30M[1]
Across 1 sourced roundDerived
  1. [1] Equity raised: Sum of the 1 sourced equity round in the funding history below (debt, tender offers and rumored rounds excluded), October 30, 2026

Is something wrong on this page?

Recent changes

  1. Oct 30, 2026Raised $30M Series A Pulse2
  2. Jul 29, 2026Raised $24.9M SEC EDGAR Form D

Funding history

2 equity events · newest first · sources dated per row
DateRoundAmountValuationLead investorsSource
Oct 30, 2026Series A$30M—
—
WithMetis MedTech
Pulse2Pulse story
Jul 29, 2026Funding roundnot counted$24.9M—
—
SEC EDGAR Form D

Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.

Funding timeline · 2 rounds · $55M tracked
$0.0M$17M$34M$25MRoundJul 26$30MSeries AOct 26

Latest Pulse

  1. Pulse's $82M Median Round Towers Over This Week's $11M ChecksValue Add Pulse's tracker shows $200.2 billion in disclosed venture capital at an $82 million median round, while this issue's seven fresh raises average just $11.3 million apiece -- a reminder that megarounds and the typical deal are different markets.→
  2. StimCardio Closes Oversubscribed $30M Series A For AFib WearableStimCardio Medical closed an oversubscribed $30 million Series A, led by Metis MedTech, to fund a pivotal study of Rhyvive, a wrist-worn neuromodulation device designed to cut atrial fibrillation recurrence after catheter ablation.→

Coverage Timeline

newest first
  1. Oct 30, 2026FUNDINGStimCardio Closes Oversubscribed $30M Series A For AFib Wearable$30M Series A→

All Coverage

FUNDING
StimCardio Closes Oversubscribed $30M Series A For AFib Wearable
FUNDING$30M Series A

StimCardio Closes Oversubscribed $30M Series A For AFib Wearable

StimCardio Medical closed an oversubscribed $30 million Series A, led by Metis MedTech, to fund a pivotal study of Rhyvive, a wrist-worn neuromodulation device designed to cut atrial fibrillation recurrence after catheter ablation.

DEEP DIVE

Related Companies

Same sector
Scribe TherapeuticsIambic TherapeuticsAttovia TherapeuticsApnimedEli LillyRetension Pharmaceuticals

StimCardio Medical FAQ

How much has StimCardio Medical raised?

StimCardio Medical has raised at least $30M in equity across 1 sourced funding round tracked by Value Add VC. The most recent was a $30M Series A in October 2026, reported by Pulse2. Debt financing, tender offers and secondary sales are not counted.

Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data ·